UK pharma wholesale: moving Britain's medicines pays 1–2%, everything around it pays ten times more

Among the 272 UK pharmaceutical wholesale and supply companies that publish a full profit-and-loss — £47.3bn of combined turnover — the companies that do the actual work of the trade earn almost none of its profit. Alliance Healthcare moved £6.64bn of medicines to Britain’s pharmacies for £73.0M of pre-tax profit, a 1.1% margin; Phoenix Healthcare Distribution ran the other visible national network at 0.5% at the operating line (its headline £68.1M of pre-tax profit rests on £60M of dividends from group companies); Lloyds Clinical delivered £1.38bn of hospital-grade medicines to patients’ homes at 1.6% — under 1% once intragroup interest is stripped. Those margins are not a failure — they are the design. The NHS reimbursement machinery is built to strip profit out of the middle of the medicine supply chain, and it works. The money in this category sits everywhere except the middle: in the drugmakers’ UK trading arms that share the shelf (Astellas at 12.5% headline, about half of it group dividends), and in a tier of remarkably lean import, specials and licence-holding houses — parallel importer Drugsrus keeps 15.2p in the pound on £55.6M by buying medicines where Europe prices them lower. Figures are approximate — verify against a company’s own accounts before relying on any single number.

Read the shelf first

Three things change how you read every number below.

Most of this category’s turnover isn’t wholesaling. The biggest names here by revenue are pharmaceutical manufacturers’ UK entities, not distributors. ViiV Healthcare Trading Services books £6.07bn of the HIV venture’s sales through a company with six employees; Haleon UK Trading Services books £3.90bn of consumer-health revenue the same way. These are in-house booking hubs — their revenue is real but their “margin” is a transfer-pricing outcome, decided in a tax department, not won in a market. Much of it is not even UK sales: ViiV’s £6.07bn is overseas revenue booked through the UK entity. They belong on the map (they are a large share of the £47.3bn) but in no competitive comparison.

Three revenue models share one shelf, and their margins must never be compared. Full-line distributors buy and sell the nation’s medicine flow at regulated, clawed-back pennies. Manufacturers’ sales arms earn whatever margin the group’s transfer pricing leaves in the UK. Import, specials and licence houses own an arbitrage or a product licence and keep the spread. A distributor at 1% can be a better-run business than a licence holder at 25%; the number measures the model, not the management.

Some filings are layered or carry non-trading income. Clarity Pharma and its parent Clarity Global Group appear with identical figures — one business, counted once below. Genus Pharmaceuticals Holdings shows a “163% margin” (£13.9M of profit on £8.6M of turnover) — that is holding-company income, not trading, and it is excluded from every read. Abbott Laboratories’ £266.6M of profit on £639.9M (41.7%) almost certainly carries group income on top of UK trading; treat it as a group entity, not a margin benchmark.

The giants

The top of the market, sorted by turnover — with what each company actually is, because the labels matter more than the ranks here.

Haleon appears twice — a booking hub and the UK sales company — as does GSK, its former parent. Business-type labels are directional. Abbott’s profit figure reads as a group entity’s, not a trading margin — see above. Phoenix’s £68.1M includes £60.0M of dividends from group undertakings (operating profit: £10.2M), and Lloyds Clinical’s £22.0M includes £12.0M of intragroup interest. Astellas’ figures are converted from euro-denominated accounts and include roughly €150M of dividends from subsidiaries.

Distribution is thin by design

Strip out the manufacturers and the booking hubs, and the actual wholesale trade sits in four rows of that table: Alliance Healthcare at 1.1%, Phoenix at 0.5% at the operating line (£60.0M of its £68.1M pre-tax profit is dividends from group companies — the network itself made £10.2M), Lloyds Clinical at 1.6% headline and 0.9% operating (half its profit is intragroup interest), and National Veterinary Services at 1.8% on the animal side. Four companies, £10.6bn of turnover, and on a trading basis roughly £100M of combined profit — a blended margin of about 1.0%.

That thinness is engineered. Community-pharmacy reimbursement claws back margin across the generics supply chain every quarter, and the distribution fee embedded in branded medicine prices is set to cover the cost of twice-daily deliveries to every pharmacy in the country, not much more. A full-line wholesaler’s defence is volume and discipline, and you can see it in the staffing: Phoenix held revenue at +3% while trimming headcount 4%. The one genuinely growing distribution business is Lloyds Clinical — +5% revenue and +7% staff — because clinical homecare (delivering and administering high-cost hospital medicines at home) is the one corner of distribution the NHS is actively expanding into.

The shape of the market

This is a mid-heavy, profitable trade. The £25–100M band is the largest (93 companies, 86% profitable), and profitability stays at 86–100% all the way up. The struggling tier is the sub-£1M one — 31 companies, only 39% profitable — where short-line wholesalers without scale or a niche go to fade. Between those poles, medicine supply is one of the most consistently profitable categories we’ve mapped: it just matters enormously which kind of profit.

Where the fat margins live: the trading houses

Screen the mid-market for well-run operators and two very different lists come back. One is manufacturers’ UK arms — Besins (11.0%), Britannia (12.9%), Eisai (12.4%), BioMarin (8.8%), Galen (9.9%) and seven more at 4–13% — respectable numbers that belong to global drugmakers’ UK operations, not to the wholesale trade. The other list is the actual story: headcount-light trading houses that buy, import, license and repackage medicines, and keep margins a full-line distributor could never dream of.

The pattern is people-per-pound. Medihealth (Northern) turns over £86.1M with eleven employees — nearly £8M of revenue per head, a telesales floor supplying independent pharmacies rather than a warehouse network, and a business that grew 57% in the year shown. Relonchem holds product licences and outsources everything physical — sixteen people, £15.2M of profit — but it is the UK arm of Indian drugmaker Marksans and buys most of its products from its parent’s plants, so part of that spread is group supply pricing rather than a market-won margin; its newest accounts, to March 2026, show the spread narrowing anyway, to 23.6% on £50.6M. Drugsrus runs the classic parallel-import play — buy medicines where Europe prices them lower, repackage for the UK — and its 105 staff (a repacking floor) still deliver 15.2%. At the other end of the same table, Rayburn Trading’s 3.3% with 188 staff shows what conventional van-and-warehouse wholesale pays — the moment you actually handle volume at scale, you inherit distribution economics. One caution across the whole tier: import spreads live on exchange rates and licence portfolios on a handful of products, so these margins are more volatile than the distributors’ — thin-and-stable versus fat-and-fragile is the real trade-off.

Growth, read with care

Ranked by raw growth this category flatters the wrong things. The two fastest “growers” are a young wholesaler ramping from a small base (RPH Pharma, +371% to £13.5M) and a holding-company artefact (Genus, excluded above). Recordati UK’s +72% to £334.7M at a 33.6% margin reads like portfolio moves inside a global drugmaker, not UK organic growth. The genuine signals are the companies growing fast and hiring behind it: Clinical Services International (+60% to £83.6M, staff +33%, 11.4% margin) is what real momentum looks like in this trade, and Independence Products (+65%, staff +136%) is scaling hard, though a 41.9% margin at £14.4M suggests something other than pure wholesale in the mix. Clarity Pharma (+65%, staff +47%) is buying growth at a −3% margin — revenue first, profit later, if it comes.

Market structure

The top five companies carry 43.8% of the category’s turnover and the top ten 54.3% — but read what the top of the curve contains: one real wholesaler (Alliance), two booking hubs (ViiV, Haleon Trading Services) and two manufacturers’ hubs. The actual distribution trade is far more concentrated than the chart can show — a handful of national networks move the overwhelming majority of Britain’s community-pharmacy medicines, and some of the biggest names in that trade file inside larger groups or under other classifications, so this map is a floor, not a census of the pipeline.

Ownership and vintage

Of the 272 companies, 151 are corporate-owned and 107 individual-owned — and the corporate tier is dominated by overseas parents (Swiss, Japanese, German, US, Indian drugmakers and distributors): only about 6% carry the Holdings/Bidco naming that fingerprints a buyout. But that fingerprint misses sponsors who buy operating names — two of the four featured distributors are sponsor-owned. Lloyds Clinical sits inside the Aurelius group, and National Veterinary Services’ ultimate parent, Patterson, was bought by Patient Square Capital in April 2025. This is a shelf owned mostly by the global pharmaceutical industry, with financial sponsors present but trading under operating names rather than Bidco ones.

The vintage profile says entry is very much alive. Pre-1990 companies are the largest cohort (67), but 89 of the 272 — a third of the map — were incorporated since 2010. You cannot build a new full-line distributor (the two visible here trace back through decades of consolidation), but a short-line wholesaler, importer or specials house needs a licence, a compliant warehouse and working capital — and the steady stream of new entrants shows people keep taking that bet.

What the map shows

1. Moving the medicines pays 1–2%, by design. Alliance Healthcare (1.1%), Phoenix (0.5% at the operating line — its headline profit rests on £60M of group dividends), Lloyds Clinical (1.6% headline, 0.9% operating) and National Veterinary Services (1.8%) — £10.6bn of turnover for roughly £100M of trading profit, a blended 1.0%, because NHS reimbursement is engineered to strip margin out of the middle.
2. Most of the £47bn isn’t wholesaling. The turnover ranks are dominated by drugmakers’ UK trading arms and booking hubs — ViiV books £6.07bn through six employees — whose margins are transfer-pricing outcomes, not market ones.
3. The fat margins belong to headcount-light trading houses. Licence holders, parallel importers and specials suppliers — Drugsrus at 15.2% on parallel imports, Clinical Services International at 11.4% with 24 staff — earn in spreads and licences what distributors can’t earn in volume; the trade-off is thin-and-stable versus fat-and-fragile.
4. Never blend the three models. Distributor, manufacturer’s arm and trading house margins measure different businesses; every honest read of this category starts by separating them.
5. Clinical homecare is distribution’s one growth lane — Lloyds Clinical growing revenue and headcount together while the conventional networks defend margin by trimming staff.
6. Entry keeps happening at the trading end. A third of the map was incorporated since 2010; the licence-and-warehouse end of medicine supply is still an open game, even though the national-network end is closed.

Methodology and caveats

This covers only the UK pharmaceutical wholesale and supply companies that publish a full profit-and-loss — 272 of a wider register of 545, so the long tail filing small-company accounts is invisible here, and some large medicine-supply names file under other classifications or inside broader groups, making this map a floor rather than a census. Business-type labels (distributor, booking hub, importer, licence holder) are directional, inferred from the accounts and public descriptions. Booking-hub and group entities are identified and excluded from competitive reads; where a parent and subsidiary both appear with identical figures, the business is counted once. Manufacturers’ UK margins reflect group transfer pricing and should not be read as UK competitive performance. Figures are approximate — verify against a company’s own accounts before relying on any single number. This is analysis, not financial advice.